Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
June 27, 2023 08:30 ET
|
Artelo Biosciences
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy ART26.12 targeting global neuropathic...
Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
June 26, 2023 08:30 ET
|
Artelo Biosciences
ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ART12.11 aims to address unmet needs within the...
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
June 07, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
April 25, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
March 31, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
February 02, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
January 26, 2023 08:30 ET
|
Artelo Biosciences
CEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26,...
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 08:00 ET
|
Artelo Biosciences
Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End $19.5 Million in Cash and Investments as of September 30, 2022 SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo...
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
September 22, 2022 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...